LON:PXS Provexis (PXS) Share Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free PXS Stock Alerts GBX 0.65 0.00 (0.00%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range 0.62▼ 0.6550-Day Range 0.55▼ 0.7352-Week Range 0.41▼ 0.90Volume199,198 shsAverage Volume842,292 shsMarket Capitalization£14.43 millionP/E Ratio43.75Dividend Yield5.06%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsStock AnalysisChartCompetitors Get Provexis alerts: Email Address Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. About ProvexisProvexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in various foods, beverages, and dietary supplement formats. It offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and heart function. The company sells its products through distributors and online channels. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.Read More PXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PXS Stock News HeadlinesMarch 15, 2024 | msn.comPXS Stock Earnings: Pyxis Tankers Beats EPS, Beats Revenue for Q4 2023February 27, 2024 | seekingalpha.comPyxis Tankers: Bet On A Strong MR Product Tankers MarketMay 4, 2024 | Behind the Markets (Ad)Investors Alert: The Next Big Thing in Weight LossUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year.January 6, 2024 | finance.yahoo.comWill Provexis (LON:PXS) Spend Its Cash Wisely?December 15, 2023 | uk.investing.comFenbo Holdings Ltd (FEBO)November 17, 2023 | benzinga.comPyxis Tankers's Earnings: A PreviewNovember 9, 2023 | morningstar.comPyxis Tankers Inc PXSSeptember 14, 2023 | finance.yahoo.comPXS.L - Provexis plcMay 4, 2024 | Behind the Markets (Ad)Investors Alert: The Next Big Thing in Weight LossUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year.June 28, 2023 | finance.yahoo.comPXS - Pyxis Tankers Inc.April 9, 2023 | finance.yahoo.comProvexis plc (NZCA.F)March 9, 2023 | lse.co.ukDefinition of 'Claims Processing Unit (CPU)'December 30, 2022 | finance.yahoo.comWe're Not Worried About Provexis' (LON:PXS) Cash BurnDecember 1, 2022 | msn.comPyxis Tankers Inc. (PXS) Is a Trending Stock: Facts to Know Before Betting on ItNovember 15, 2022 | seekingalpha.comPyxis Tankers Inc. (PXS) Q3 2022 Earnings Call TranscriptNovember 15, 2022 | msn.comPyxis Tankers Inc. (PXS) Tops Q3 Earnings and Revenue EstimatesOctober 17, 2022 | msn.comPyxis Tankers Inc. (PXS) Gains But Lags Market: What You Should KnowSeptember 22, 2022 | uk.finance.yahoo.comProvexis plc (PXS.L)May 18, 2022 | lse.co.ukBattered stocks inch up; S. African rand falls on power cuts, growth fearsApril 2, 2022 | finance.yahoo.comHere's Why We're Not At All Concerned With Provexis' (LON:PXS) Cash Burn SituationOctober 14, 2021 | nasdaq.comMarket Sentiment Around Loss-Making Pyxis Tankers Inc. (NASDAQ:PXS)October 4, 2021 | finance.yahoo.comWe're Interested To See How Provexis (LON:PXS) Uses Its Cash Hoard To GrowJuly 23, 2021 | markets.businessinsider.comProvexis PLC : Price Monitoring ExtensionSee More Headlines Receive PXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Provexis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/30/2020Today5/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:PXS CUSIPN/A CIKN/A Webwww.provexis.org Phone+44-1753-861777FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio43.75 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net Margins-83.03% Pretax MarginN/A Return on Equity-75.88% Return on Assets-36.73% Debt Debt-to-Equity RatioN/A Current Ratio2.41 Quick Ratio6.21 Sales & Book Value Annual Sales£426,168.00 Price / Sales33.86 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares2,220,000,000Free FloatN/AMarket Cap£14.43 million OptionableNot Optionable Beta1.24 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Ian Ford BA (Hons) ACA (Age 59)F.C.A., CEO, CFO, Company Secretary & Executive Director Comp: $174.89kDr. Niamh Ann O'Kennedy B.Sc. (Age 51)BSc, M.Sc., MSc, Ph.D., Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Comp: $99.05kProf. Asim K. Duttaroy BS MS Ph.D.DSc FICN, Consultant & Member of Scientific Advisory BoardKey CompetitorsChill Brands GroupLON:CHLLShield TherapeuticsLON:STXArgent BioPharmaLON:MXCDiurnal GroupLON:DNLVenture Life GroupLON:VLGView All Competitors PXS Stock Analysis - Frequently Asked Questions How have PXS shares performed in 2024? Provexis' stock was trading at GBX 0.65 at the start of the year. Since then, PXS stock has increased by 0.0% and is now trading at GBX 0.65. View the best growth stocks for 2024 here. How were Provexis' earnings last quarter? Provexis plc (LON:PXS) announced its earnings results on Wednesday, September, 30th. The company reported ($0.02) earnings per share for the quarter. Provexis had a negative net margin of 83.03% and a negative trailing twelve-month return on equity of 75.88%. What other stocks do shareholders of Provexis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Provexis investors own include Taylor Wimpey (TW), ValiRx (VAL), Sirius Minerals (SXX), Lloyds Banking Group (LLOY) and easyJet (EZJ). How do I buy shares of Provexis? Shares of PXS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:PXS) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldInvestors Alert: The Next Big Thing in Weight LossBehind the MarketsElon to Transform U.S. Economy? Porter & CompanyCould Your Accounts Be Frozen?Allegiance GoldAutomatic Income (from home)Awesomely, LLCThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe asset beating inflation by 4xColonial MetalsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provexis plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
